Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | CMA1 | P23946 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417318 | 0.93 | KDM4E (0.42) | KMT2AHTTMEN1KDM4EHPGD | |
| SCHEMBL5533348 | 0.91 | HTT (0.42) | KMT2AHTTMEN1LMNAMAPK1 | |
| SCHEMBL5530220 | 0.91 | CYP3A4 (0.44) | LMNAKDM4EHPGDALDH1A1TOP1 | |
| SCHEMBL5519872 | 0.89 | HTT (0.44) | KMT2AHTTMEN1LMNAMAPK1 | |
| SCHEMBL5525438 | 0.88 | ALDH1A1 (0.45) | KMT2AHTTMEN1LMNAMAPK1 | |
| SCHEMBL5525609 | 0.86 | ALDH1A1 (0.41) | KMT2AHTTMEN1LMNAMAPK1 | |
| SCHEMBL5526204 | 0.84 | STAT3 (0.46) | KMT2AHTTKDM4EHPGDCYP2C19 | |
| SCHEMBL5530189 | 0.83 | CYP3A4 (0.46) | LMNAKDM4EHPGDALDH1A1TOP1 | |
| SCHEMBL5528707 | 0.82 | STAT3 (0.46) | KMT2AHTTMEN1LMNAMAPK1 | |
| SCHEMBL5526755 | 0.81 | HPGD (0.45) | HTTKDM4EHPGDALDH1A1TOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | KMT2A 2389/4885HTT 3021/4885MEN1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.